In last trading session, Trevi Therapeutics Inc (NASDAQ:TRVI) saw 3.6 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $4.80 trading at $0.23 or 5.03% at ring of the bell on the day assigns it a market valuation of $428.95M. That closing price of TRVI’s stock is at a premium of 2.5% from its 52-week high price of $4.68 and is indicating a premium of 52.08% from its 52-week low price of $2.30.
For Trevi Therapeutics Inc (TRVI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.10. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.11 in the current quarter.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Upright in the green during last session for gaining 5.03%, in the last five days TRVI remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $4.80 price level, adding 1.84% to its value on the day. Trevi Therapeutics Inc’s shares saw a change of 16.50% in year-to-date performance and have moved 18.52% in past 5-day. Trevi Therapeutics Inc (NASDAQ:TRVI) showed a performance of 35.02% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 20.0% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -25.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -25.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 27.24% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -67.11% while estimates for its earnings growth in next 5 years are of -24.56%.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
NEA MANAGEMENT COMPANY, LLC is the top institutional holder at TRVI for having 11.37 million shares of worth $33.88 million. And as of 2024-06-30, it was holding 11.2532 of the company’s outstanding shares.
The second largest institutional holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., which was holding about 7.38 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4169 of outstanding shares, having a total worth of $22.0 million.
